ATLASense Biomed

Company Overview

Snapshot

Founded in June 2015 by Tal Or, ATLASense Biomed operates with 11–50 employees. The company has secured $2.81M in total capital across six funding rounds. In February 2025, ATLASense Biomed unveiled its REPHAEL platform, marking a significant advancement in remote health monitoring.

Business overview

ATLASense Biomed develops wearable solutions for clinical decision support, focusing on transitioning healthcare safely and cost-effectively from hospitals to homes. Its core product, REPHAEL, is a wearable platform designed for ICU-level monitoring and predictive insights, capable of detecting and alerting healthcare teams to critical risks like respiratory failure, sepsis, and heart failure days before they escalate. The company serves the healthcare industry, operating within the Health Tech & Life Sciences sector, specifically in digital healthcare and patient remote monitoring.

Strategic signal

In February 2025, ATLASense Biomed unveiled its REPHAEL platform, which revolutionizes remote health monitoring by providing ICU-level precision and predictive insights through a reusable, economical device. This launch signals the company's commitment to advancing home-based care and positions it as a key innovator in the digital healthcare landscape, offering a solution that can significantly reduce healthcare costs and improve patient outcomes by enabling early detection of critical health risks.

Company Intelligence Q&A

What is ATLASense Biomed's primary focus?

ATLASense Biomed focuses on developing wearable solutions for clinical decision support, aiming to transition healthcare from hospitals to homes safely and cost-effectively, while preventing life-threatening events.

What is the REPHAEL platform?

The REPHAEL platform is ATLASense Biomed's wearable solution that delivers ICU-level monitoring and predictive insights for patients in various settings, including hospitals and homes. It is designed to detect and alert healthcare teams to critical risks like respiratory failure, sepsis, heart failure, and falls, days before they escalate.

When did ATLASense Biomed unveil its REPHAEL platform?

ATLASense Biomed unveiled its REPHAEL platform in February 2025, marking a new era in remote health monitoring.

What recognition did ATLASense Biomed receive in 2020?

In March 2020, ATLASense Biomed earned the top prize in Henry Ford Health System's Global Health Tech Challenge for its patient monitoring system.

What is the total funding raised by ATLASense Biomed?

ATLASense Biomed has raised $2.81 million in total capital across six funding rounds.